Skip to content
DataLookout
Menu

INVINCIBLE-3NCT06263231

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 37 words
    • Trial sites expanded: 17 → 20 locations
    • Collaborator revised
    • Publications: details revised at 20 of 21 entries
  2. Notable Enrollment reopened
    • Site details revised at 17 of 17 sites
    v11
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 17 of 17 sites
    v10
  4. Minor Study sites: 15 to 17v9
  5. Minor Study sites: 13 to 15v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 10 to 13v7
  2. Minor Study sites: 9 to 10v6
  3. Minor Study sites: 4 to 9v5
  4. Notable Eligibility criteria shortened, about 51 words
    • Study sites: 1 to 4
    • Study title expanded, about 1 word
    v4
  5. Minor Start date changed from estimate of Jun 2024 to Jun 28, 2024v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.

Secondary (2)

Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with leiomyosarcoma
Overall Survival (OS) For INT230-6 Compared to OS for Standard of Care (SOC) for Participants with liposarcoma

Arms and interventions

INT230-6 MonotherapyExperimental

INT230-6 administered intratumorally. Participants will be dosed every 2 weeks (± 2 days) for up to a total of 5 treatment sessions (e.g., Days 1, 15, 29, 43 and 57). Once the participant has completed the treatment phase, they will continue into a 22-month maintenance phase, where investigators may inject new lesions or previously injected lesions with up to 175 mL of INT230-6 every 12 weeks (Q12W) ± 14 days. Dose volume in a session is dependent on the participants presenting tumor burden.

US Standard of CareActive comparator

Participants in this arm may receive any of the following depending on soft tissue sarcoma (STS) subtype and PI preference: * Pazopanib: 800 mg PO every day until clinical deterioration or disease progression * Trabectedin: 1.5 mg/m2 body surface area as 24-hour IV infusion every 3 weeks until clinical deterioration or disease progression * Eribulin: Non- European Union (EU) sites: 1.4 mg/m2 eribulin mesylate body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression EU sites: 1.23 mg/m2 (free base) body surface area IV on Days 1 and 8 every 3 weeks until clinical deterioration or disease progression

Drugs: INT230-6, Eribulin, Trabectedin, Pazopanib

Sites

20 sites in 5 countries

United States 13, Spain 3, Germany 2, Canada 1, France 1